In less than three months, Uganda is expected to join three other African countries where an injectable drug has been approved for HIV/Aids prevention....CONTINUE READING
This significant development was revealed by the Uganda Aids Commission (UAC), touting it as an effective, safe, and user-friendly approach to disease prevention in comparison to existing methods.
The long-lasting injectable cabotegravir (CAB-LA) has been verified as effective and is considered a key element in national efforts to reduce the health burden of HIV/AIDS.
The UAC plans to introduce the drug early next year, with initial targets set at 10,000 people in the first year and a gradual increase in subsequent years. However, specific criteria for selecting the first beneficiaries have not been disclosed.
This innovative drug, endorsed by the World Health Organization (WHO), has been proven safe and effective in preventing HIV infection and is considered more convenient than oral pills.
Its national approvals are anticipated to be ready by the end of the year, making injectable PrEP accessible to Ugandans from January onwards, and it will be provided free of charge.
This development marks a pivotal moment in the ongoing battle against HIV/AIDS, particularly in a nation where it has claimed many lives. Uganda has suffered significantly from the HIV/AIDS epidemic, with 17,000 lives lost to the disease in the past year.
The introduction of the injectable PrEP could be a game-changer in addressing this pressing health issue, with the hope of making significant progress in combating the epidemic…CONTINUE READING>>
